http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-960037046-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-40 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-395 |
| filingDate | 1995-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1996-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-960037046-A |
| titleOfInvention | Ophthalmic Formulation for the Treatment of Myopia and Glaucoma Including Dopamine Receptor Stimulant |
| abstract | The present invention relates to an ophthalmic formulation for treating myopia and glaucoma comprising a dopamine receptor stimulant, wherein the ophthalmic formulation comprising the dopamine receptor stimulant and cyclodextrin or a derivative thereof as an essential component is controlled by the physiological pH of the eye and stimulated to the eye. Without omission, since the transition to the plasma during eyedrop administration is excellent and the transition to eye tissues such as the retina is excellent, it can be used more effectively in the treatment by the topical administration and glaucoma treatment. |
| priorityDate | 1995-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 20.